Sterix Limited

Eberhard Unger

Alexander Hillisch

Olaf Peters

Gerhard Siemeister

Christian Gege

Dirk Kosemund

Ulrich Bothe

Bernd Menzenbach

Wilko Regenhardt

Jens Hoffmann

Sigfrid Schwarz

Thomas Michel

Ina Scherlitz-Hofmann

Tobias Neumann

The invention relates to the use of 2-substituted estra-1,3,5(10)-triene-3-yl sulfamates of general formula I, in addition to their pharmaceutically acceptable salts for producing a medicament. Said compounds have an anti-tumour action. 

2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumor action

The present invention relates to the use of 2-alkoxyestrogen sulfamates of general formula I wherein The inventive compounds are distinguished by the 2-alkoxy substitution in conjunction with the 17-hydroxy substitution. They have a special effect with regard to inhibiting tubulin polymerization and can be used, for example, for the treatment of prostate cancers.

Antitumor-active 2-alkoxyestradiol sulfamates

This invention relates to 2-substituted D-homo-estra-1,3,5(10)-trien-3-yl sulfamates of general formula I (I), in which R3 means a C1-C5-alkyl or C1-C5-alkyloxy group as well as their use for the production of a pharmaceutical agent for treating tumor diseases, which can be influenced positively by the inhibition of tubulin polymerization. The compounds according to the invention are distinguished by a D-homo-substitution. They have a special action with respect to tubulin polymerization inhibition and can be used, for example, for treating prostate cancer

Antitumoral D-homoestra-1,3,5(10)-trien-3-yl 2-substituted sulfamates

Disclosed are compounds of formula I and use thereof in a method of treating a tumor disease that can be influenced positively by the inhibition of tubulin polymerization.

2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action

This invention relates to 2-substituted D-homo-estra-1,3,5(10)-trien-3-yl sulfamates of general formula I (I), in which R3 means a C1-C5-alkyl or C1-C5-alkyloxy group as well as their use for the production of a pharmaceutical agent for treating tumor diseases, which can be influenced positively by the inhibition of tubulin polymerization. The compounds according to the invention are distinguished by a D-homosubstitution. They have a special action with respect to tubulin polymerization inhibition and can be used, for example, for treating prostate cancer 

Antitumoral d-homoestra-1,3,5 (10)-trien-3-yl 2-substituted sulfamates

Growing community of inventors

Cospeda, Germany

Eberhard Unger